Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of SU 011248 in Head And Neck Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent and/or metastatic head and neck squamous cell carcinoma not amenable to curative treatment with surgery and/or chemotherapy and/or radiation~* Recurrence must be confirmed by anatomopathology (cytology or biopsy)~* At least one measurable lesion by MRI or CT-scan~* Failed or relapsing after first line chemotherapy including a platinum\* or a taxane-based chemotherapy regimen~* Patients ineligible for chemotherapy could be included in first line~* ECOG performance status 0 -2, in stable medical condition~* Patients must be able to swallow tablets~* Patients must have an expected survival of at least 3 months~* Paraffin-embedded tumor tissue available for immunohistochemistry~* Patients must be over 18 years old and must be able to give written informed consent~* Women of child-bearing age must have a negative pregnancy test~* Female patients of child-bearing age must use effective contraception until 3 months have elapsed after the last injection~* Patients must have normal organ function~* For patients with local recurrence and easily accessible tumors, acceptance of iterative biopsies to store tumor samples (Formaldehyde for immunochemistry, RNA later)~* Acceptance of giving 20 ml of blood for eventual pharmacogenomic analysis~* Acceptance of giving two plasma samples (3ml) at baseline and after 4 weeks of treatment with SU011248~* Signed informed consent prior to beginning protocol specific procedure~Exclusion Criteria:~* Non-squamous head and neck cancer~* Nasopharynx cancer~* Brain metastases~* More than two lines of chemotherapy for palliative treatment (except if chemotherapy was given as a part of a multimodal treatment given with a curative intent)~* Surgery or irradiation or investigational drugs within 4 weeks before study inclusion~* Other uncontrolled illnesses (active infections requiring antibiotics, bleeding disorders, ...)~* Active uncontrolled coronary disease or cardiac insufficiency (Ejection fraction below 40%)~* Previous malignancy, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Other concomitant anticancer therapies~* Previous treatment with anti-VEGF, PDGF, or kit therapies. EGFR therapy is not an exclusion criteria.~* Organic brain syndrome or significant psychiatric abnormality that would preclude participation in the full protocol and follow up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): patients will receive SU011248 in monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).